NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NGM Biopharmaceuticals, Inc.

A biotechnology company focused on translating complex, powerful biology into life-changing medicines.

NGM Bio

NGM Bio is a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. In addition to a healthy balance sheet and cash runway, the company currently has four programs in active clinical development. Visit us at www.ngmbio.com for more information.


Prospect Venture Partners

Topspin Partners

Rho Ventures

Solon Mack Capital

The Column Group

Tichenor Ventures

Greenspring Associates

Merck

NGM Biopharmaceuticals

We're thrilled to announce a $122M Series A financing, led by The Column Group with participation from a select group of investors. 

Read press release: https://bit.ly/3LuwvU4
 
These funds will enable us to initiate a planned registrational trial of aldafermin for the treatment of primary sclerosing cholangitis and complete a planned Phase 2 proof-of-concept trial for the treatment of hyperemesis gravidarum (HG) - both expected to begin in Q4 2024. 
 
PSC is a rare liver disease that irreparably damages the bile ducts, leading to bile acid dysregulation and, ultimately, severe liver damage. HG is a rare, debilitating condition of pregnancy, characterized by intractable nausea and uncontrollable vomiting and frequent, serious complications. 
 
There are no currently approved therapies for PSC or HG.

#primarysclerosingcholangitis #hyperemesisgravidarum #hyperemesis

Today we were pleased to present positive Phase 2b results from the ALPINE 4 trial of aldafermin in patients with compensated cirrhosis (F4) due to #NASH at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in Boston. #TLM23
 
Press release:  https://bit.ly/40BAyES
Presentation:  https://bit.ly/47engAW

We're thrilled to announce today that Jean-Frederic Viret, Ph.D. has been appointed Chief Financial Officer of NGM Bio!  Read more:  https://bit.ly/49dVLc5

COM:NGMBIO

NGM Bio

Last Close

1.56

04/04 20:00

Market Cap

128.53M

Beta: -

Volume Today

2.21M

Avg: -